HIV prevention jab set for roll-out next year as key groups hail relief

HIV sensitisation. [Courtesy]

Kenya is set to roll out Lenacapavir, a long-acting injectable HIV prevention drug, from January 2026 in a major shift expected to boost adherence, reduce stigma and expand protection, especially among vulnerable groups.

The Ministry of Health, through the National AIDS and STI Control Programme (NASCOP), announced the approval of the drug this week, positioning Kenya among early adopters globally.